Pricing Log in Create free account
Friday 6 November 2026 Export TCMD’s income statement to Excel — free account

Tactile Systems Technology, Inc.

TCMD Healthcare Medical Devices

Tactile Systems Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $329.5 million, up 12.5% from fiscal 2024.

Revenue
+7.12%
EPS
−14.5%
Free cash flow
+23.8%

Quarter to September 2026, against a year earlier

25.96 0.41 −1.55%
Market cap
$590.7M
P/E
25.2×
Fwd P/E
20.6×
Dividend yield
—
F-score
8/9
Altman Z
9.61
Beneish M
−2.82
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.14
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — 1 6 — — 1 — — 1 — — 1
Insider Ownership 4.34%

Capital & Financial Ratios $m

Size
Market Cap 590.72
Revenue ttm 356.42
Net income ttm 23.82
Free cash flow ttm 28.86
Net debt Q (90.02)
Valuation
P/E 25.17
Forward P/E 20.60
Price / sales 1.67
Forward P/S Powerpack
Price / FCF 20.66
Price / book 2.62
Financial health
Current ratio Q 3.51 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 479.55
Growth
Revenue growth Q +7.12% (above 0%: growing)
Operating income growth Q −12.51% (below 0%: shrinking)
EPS, this year +37.80% (at or above 15%: strong)
EPS, next year A +32.45% (at or above 15%: strong)
Revenue, next year A +9.98%
EPS, past 5 yrs —
EPS, next 5 yrs A +33.82% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.5×, against a ten-year median of 2.0×; over the ten years it ranged from 0.4× in 2016 to 10.1× in 2018.
P/E against its own 10 years 28.67%
10-year low 10-year high
P/S against its own 10 years 39.55%
10-year low 10-year high
P/B against its own 10 years 37.65%
10-year low 10-year high
EV/Sales against its own 10 years 38.93%
10-year low 10-year high
EV/FCF against its own 10 years 39.53%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 75 109 99 90
Receivables 43 45 44 49
Inventory 23 19 14 16
Other — — — —
145 178 165 167
2023 2024 2025 Q'26
Payables 7 6 5 12
ST’ Debt — — — —
Other 4 3 3 7
41 41 41 47

Compound Annual Growth %

10y 5y 3y
Sales 18.02% 11.98% 10.12%
Cash Flow 33.40% 72.61% 101.81%
Earnings 0.00% 0.00% 0.00%
Book Value 23.15% 11.90% 21.71%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.30 Actual 0.31

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.44 0.46 Beat by 0.02
Q1 FY26 −0.07 −0.08 Miss by 0.01
Q2 FY26 0.14 0.34 Beat by 0.20
Q3 FY26 0.30 0.31 Beat by 0.01
Q4 FY26 0.54 — Reports 16 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.08) 0.34 0.31 — —
’25 (0.13) 0.14 0.36 0.46 0.82
’24 (0.09) 0.18 0.21 0.40 0.70
’23 (0.09) 0.00 0.94 0.35 1.23
’22 (0.78) (0.23) (0.11) 0.23 (0.89)
’21 (0.12) 0.07 (0.17) (0.38) (0.60)
’20 (0.07) (0.72) 0.12 0.61 (0.03)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 75 86 92 — —
’25 61 79 86 104 330
’24 61 73 73 86 293
’23 59 68 70 78 274
’22 48 60 65 74 247
’21 43 51 52 62 208
’20 44 35 49 59 187
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 3 12 — —
’25 0 15 10 17 43
’24 1 13 10 16 41
’23 (1) 14 4 18 36
’22 (3) 2 2 4 5
’21 (1) (1) (1) 6 3
’20 1 (9) 6 5 3
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) 2 11 — —
’25 0 14 9 17 40
’24 0 13 9 16 38
’23 (1) 13 4 17 33
’22 (3) 2 1 4 3
’21 (1) (2) (2) 5 0
’20 1 (9) 5 5 1
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 85 109 144 189 187 208 247 274 293 330 356 +16.3% 362 397 433 +9.5%
Gross margin, % 72.87 73.45 71.14 70.84 70.97 71.24 71.31 71.11 73.96 75.91 77.00 +3.0 pt
EBT 4 4 3 11 (2) (2) (15) 16 23 31 36 +24.7%
EBT margin, % 5.10 3.83 2.42 5.87 (1.21) (1.10) (6.27) 5.75 8.02 9.51 10.12 +4.4 pt
Net income 3 6 7 11 (1) (12) (18) 29 17 19 24 +23.4%
Per share, $
Per share, $ Revenue 9.49 6.30 7.88 10.02 9.67 10.55 12.30 11.97 12.27 14.41 15.75 +4.8%
Earnings 0.18 0.34 0.36 0.58 (0.03) (0.60) (0.89) 1.24 0.71 0.83 1.05 +18.5%
Cash flow 0.79 0.24 0.49 0.13 0.14 0.13 0.26 1.56 1.70 1.87 1.42 +10.1%
Capex (0.09) (0.22) (0.52) (0.32) (0.12) (0.12) (0.10) (0.11) (0.10) (0.11) (0.15) +1.9%
Free cash flow 0.70 0.02 (0.03) (0.18) 0.03 0.01 0.16 1.46 1.60 1.76 1.28 +10.9%
Book value 6.69 4.19 4.89 5.95 6.45 6.50 6.05 8.45 9.07 9.57 10.04 +4.1%
Shares, m 9 17 18 19 19 20 20 23 24 23 23 +11.0%
Valuation, ×
Valuation, × P/E 297.35 87.00 124.05 116.40 0.00 0.00 0.00 11.81 24.47 34.12 25.17 69.5
P/S 1.66 4.70 5.78 6.74 4.65 1.80 0.96 1.19 1.40 2.01 1.67 3.1
P/B 2.35 7.05 9.31 11.34 6.97 2.93 1.96 1.69 1.89 3.03 2.62 4.9
EV/Sales 1.16 4.30 5.46 6.54 4.44 1.86 1.00 1.01 1.10 1.78 1.48 2.9
EV/FCF 15.86 1,261.97 (1,457.41) (356.23) 1,650.65 1,399.75 74.44 8.31 8.48 14.55 18.29 262.0
Cash, $m
Cash, $m Operating cash flow 7 4 9 3 3 3 5 36 41 43 32 +22.2%
Capex (1) (4) (10) (6) (2) (2) (2) (2) (2) (3) (3) +13.2%
Free cash flow 6 0 (1) (3) 1 0 3 33 38 40 29 +23.1%
Balance, $m
Balance, $m Working capital 50 62 69 87 97 79 55 104 137 124 119 +10.5%
Net debt (42) (44) (46) (38) (39) 11 8 (49) (86) (99) (90) +10.1%
Shareholders’ equity 60 73 89 113 125 128 121 194 217 219 227 +15.5%
Returns, %
Returns, % ROA 2.94 7.21 6.77 8.48 (0.38) (5.65) (7.16) 10.63 5.85 6.67 8.65 +3.7 pt
ROIC 14.88 8.44 4.31 8.83 (2.65) (0.79) (6.17) 7.80 10.59 15.29 15.33 +0.4 pt
ROE 6.05 8.84 8.17 10.87 (0.52) (9.34) (14.31) 18.10 8.27 8.77 11.02 +2.7 pt
People
People Employees 335 406 499 629 707 988 982 992 1,037 1,086 — +14.0%
Revenue/emp, $m 0.25 0.27 0.29 0.30 0.26 0.21 0.25 0.28 0.28 0.30 — +2.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Tactile Systems Technology, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VREX VAREX IMAGING $783.0M 34.8× 39.2× +3.69% (above 0%: growing) n/m +757.14% (above 0%: growing) 36.44% 10.83% Compare
PACB Pacific Biosciences of California, Inc. $755.3M — (loss-making) — (loss-making) +5.52% (above 0%: growing) n/m −101.95% (below 0%: shrinking) 33.21% (91.22%) Compare
CTKB Cytek Biosciences, Inc. $701.9M — (loss-making) — (loss-making) +1.79% (above 0%: growing) n/m −30.25% (below 0%: shrinking) 58.63% (15.82%) Compare
TCMD Tactile Systems Technology, Inc. $590.7M 25.2× 20.6× +7.12% (above 0%: growing) −14.49% (below 0%: shrinking) +23.84% (above 0%: growing) 76.74% 10.44%
AVR Anteris Technologies Global Corp. $544.0M — (loss-making) — +63.27% (above 0%: growing) n/m −6.84% (below 0%: shrinking) 76.91% (3,072.05%) Compare
SGHT Sight Sciences, Inc. $537.7M — (loss-making) — (loss-making) +25.20% (above 0%: growing) n/m +72.21% (above 0%: growing) 85.94% (24.59%) Compare
DCTH Delcath Systems, Inc. $502.8M 1,455× — (loss-making) +20.60% (above 0%: growing) −12.50% (below 0%: shrinking) −24.45% (below 0%: shrinking) 89.75% 8.22% Compare
CERS Cerus Corporation $430.2M — (loss-making) — (loss-making) +6.28% (above 0%: growing) n/m +2,471.28% (above 0%: growing) 57.12% 0.60% Compare
SENS Senseonics Holdings, Inc. $422.5M — (loss-making) — (loss-making) +117.82% (above 0%: growing) n/m −223.24% (below 0%: shrinking) 59.10% (248.48%) Compare
Median of peers $540.8M — — +13.44% — −15.64% 58.87% (20.20%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 25 March 2026

Ownership

Directors and executive officers, together 2.10%
50 Hudson Yards, New York, NY 8.00%
100 Vanguard Blvd., Malvern, PA 6.90%
1585 Broadway, New York, NY 5.70%
6300 Lamar Avenue, Overland Park, KS 5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Tactile Systems Technology, Inc. (TCMD) Latest News

3 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · The Motley Fool
Impact 3 · · The Motley Fool transcript

2 Nov

Impact 3 · · MarketBeat
Impact 3 · · The Motley Fool
Impact 3 · · GlobeNewswire

17 Aug

Impact 3 · · The Motley Fool transcript

11 Aug

Impact 3 · · Moby transcript

10 Aug

Impact 4 ·
Impact 3 · · MarketBeat transcript

13 Jul

Impact 3 ·

2 Jun

Impact 4 · · GlobeNewswire

11 May

Impact 4 · · Simply Wall St.

7 May

Impact 4 · · Simply Wall St.

4 May

Impact 4 · · Moby
Impact 4 · · MarketBeat
Impact 4 · · The Motley Fool transcript
Impact 4 · · The Motley Fool transcript
Impact 4 · · The Motley Fool transcript
Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

9 Apr

Impact 4 · · Simply Wall St.

26 Feb

Impact 3 ·

25 Feb

Impact 4 · · Simply Wall St.

24 Feb

Impact 4 · · Insider Monkey

19 Feb

Impact 4 · · Simply Wall St.

18 Feb

Impact 4 · · The Motley Fool
Impact 4 · · GuruFocus.com
Impact 3 · · Moby

17 Feb

Impact 4 · · MarketBeat
stockrow.com/TCMD · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com